Cosmo Pharmaceuticals Delivers Record 2024 Results – Completes Phase III Enrollment for Androgenetic Alopecia in males – Proposes increased dividend of €2.05 per share – reinforcing Shareholder Value and Growth Momentum into 2025
Cosmo Pharmaceuticals N.V. (“Cosmo”) today reported its unaudited results for the fiscal year ending December 31, 2024. The consolidated and audited 2024 Full-Year results along with the 2024 Annual Report and ESG Report will be published on March 21, 2025.
